ImmunoGen, Inc.
(NASDAQ : IMGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 1.14%67.561.0%$1024.31m
BIIBBiogen, Inc. -0.37%333.001.5%$704.38m
AMGNAmgen, Inc. 0.20%223.481.3%$582.04m
ILMNIllumina, Inc. 2.59%298.923.5%$424.29m
REGNRegeneron Pharmaceuticals, Inc. 0.19%399.552.6%$378.07m
VRTXVertex Pharmaceuticals, Inc. 1.55%243.821.9%$358.57m
ALXNAlexion Pharmaceuticals, Inc. -0.83%102.562.0%$204.52m
EXASEXACT Sciences Corp. 3.61%98.1824.0%$177.12m
AAgilent Technologies, Inc. 0.43%85.841.6%$157.99m
SGENSeattle Genetics, Inc. -0.13%118.076.1%$115.03m
MRNAModerna, Inc. -0.24%19.000.0%$108.13m
INCYIncyte Corp. 0.51%78.452.5%$101.70m
SRPTSarepta Therapeutics, Inc. 0.31%125.4214.6%$97.52m
BMRNBioMarin Pharmaceutical, Inc. 0.87%89.014.3%$96.71m
XLRNAcceleron Pharma, Inc. -0.48%93.666.1%$94.41m

Company Profile

ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.